Delfi Diagnostics is at the forefront of early cancer detection through its innovative fragmentomics technology, which analyzes cell-free DNA (cfDNA) fragments found in blood samples. This method leverages advanced machine learning and next-generation sequencing to identify previously unrecognized cancer-associated DNA fragments, significantly expanding the scope of detection beyond traditional liquid biopsy techniques that focus on known mutations. By examining millions of data points, the DELFI approach enhances the sensitivity and specificity of cancer screening, making it a promising tool for early diagnosis, particularly in lung cancer, where early intervention is crucial for improving patient outcomes.

The company's flagship product, the FirstLook blood test, exemplifies this technology by providing a non-invasive and efficient means of assessing lung cancer risk. With a negative predictive value of 99.8%, FirstLook integrates whole-genome sequencing and machine learning to analyze DNA fragment patterns, offering clear results that guide further screening decisions. Delfi's commitment to ongoing innovation is evident in its plans to expand its product offerings, utilizing the DELFI platform for monitoring and minimal residual disease applications across various cancer types, thereby addressing significant unmet medical needs in oncology.

United States

DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.

Delfi Diagnostics

Company Details